Daiichi Sankyo Co Ltd 2014 Annual Report with Sustainability Disclosures
Company: Daiichi Sankyo Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2014
Type: Annual Report with Sustainability Disclosures
Pages: 94
The report presents Daiichi Sankyo Group's value-creation model linking pharmaceutical innovation with responsible corporate activities and reports fiscal 2013 consolidated revenue of ¥1,118.2 billion. It highlights global development and regulatory submissions for edoxaban, alongside launches of prasugrel and other products. Sustainability disclosures cover compliance, human resources, access to medicines, social contribution and environmental management; FY2013 group emissions were 537,404 t-CO2, comprising Scope 1 of 210,324 t-CO2 and Scope 2 of 327,079 t-CO2. The report also records UN Global Compact participation and inclusion in major sustainability indexes, including the CDP Climate Performance Leadership Index.
Services
From bulk PDFs to structured indicators and machine-readable documents.